Abstract:Background: The hallmarks of hepatic ischemia/reperfusion (I/R) injury, a common clinical problem that occurs during liver surgical procedures, include severe cell death and inflammatory responses that contribute to early graft failure and a higher incidence of organ rejection. Unfortunately, effective therapeutic strategies are limited. β-arrestins are multifunctional proteins that mediate receptor desensitization and serve as important signaling scaffolds in numerous physiopathological processes. However, the role of β-arrestins in hepatic I/R remains largely unknow. Methods: We overexpressed Arrb1 in the hepatocyte of C57BL/6 mice using an Arrb1 adeno-associated virus. Wide-type, Arrb1 overexpressing and knockout mice were subjected to a partial (70%) hepatic ischemia for 60 minutes, followed by various periods of reperfusion. Isolated hepatocytes from different group of mice were subjected to hypoxia-reoxygenation (H/R) injury to determine the in vitro effects of Arrb1. The molecular mechanisms underlying Arrb1-regulatd hepatic I/R injury were further explored and verified in mice. Findings: Here, we showed that only Arrb1 was downregulated during I/R-injured liver injury. Hepatocyte-specific overexpression of Arrb1 significantly ameliorated liver damage, as demonstrated by decreases in serum aminotransferases, hepatocellular necrosis and apoptosis, infiltrating inflammatory cells and secretion of pro-inflammatory cytokines relative to control mice. Whereas, experiments with Arrb1 knockout mice reveled opposite effects. Mechanistically, Arrb1 directly interacts with TRAF6 in hepatocyte, and inhibits the ubiquitination of TRAF6, which then prevents the activation of the downstream MAPK and NF-κB signaling pathways during hepatic I/R injury. Interpretation: The Arrb1-TRAF6 interaction inhibited the ubiquitination of TRAF6 and the activation of MAPK and NF-κB signaling, and then protected against cell death and inflammation, suggesting Arrb1 is a potential therapeutic target for hepatic I/R injury. Funding: This research was supported by grants from the 481 National Key Research and Development Program of China (2016YFC0905900), The State Key Program of National Natural Science Foundation of China (81430062), and the Innovative Research Groups of the National Natural Science Foundation (81521004 to B.S.). The authors declare no conflicts of interest. Declaration of Interest: The authors declare no potential conflicts of interest. Ethical Approval: Animal protocols were approved by the Animal Care and Use Committee of Nanjing Medical University, and experiments were conducted in adherence with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD, USA). We gained permission from all the patients and healthy volunteers, and the procedures of our study on the basis of the basic principles of Helsinki Declaration were approved by the Ethics Committee of Nanjing Drum Tower Hospital.

β-arrestin2 Inhibits Apoptosis and Inflammation of Liver Induced by Ischemia-reperfusion in Mice via AKT and TLR4 Pathway.

Β-Arrestin 2 Promotes Hepatocyte Apoptosis by Inhibiting Akt Protein.

β-arrestin 2 attenuates lipopolysaccharide-induced liver injury via inhibition of TLR4/NF-κB signaling pathway-mediated inflammation in mice.

Β-Arrestin-2 Attenuates Hepatic Ischemia-Reperfusion Injury by Activating PI3K/Akt Signaling

ARRB1 ameliorates liver ischaemia/reperfusion injury via antagonizing TRAF6-mediated Lysine 6-linked polyubiquitination of ASK1 in hepatocytes

The Inhibition of Bruton Tyrosine Kinase Alleviates Acute Liver Failure via Downregulation of NLRP3 Inflammasome.

ARRB1 Protects Against Hepatic Ischemia-Reperfusion Injury Via Interaction with TRAF6

Β-Arrestin 2 Negatively Regulates Toll-like Receptor 4 (Tlr4)-Triggered Inflammatory Signaling Via Targeting P38 MAPK and Interleukin 10.

Arrb1 Ameliorates Liver Ischemia/Reperfusion Injury Via Interacting with TRAF6 in Hepatocytes

β-Arrestin2 deficiency attenuates oxidative stress in mouse hepatic fibrosis through modulation of NOX4

Activation of Cyclic Adenosine Monophosphate-Dependent Protein Kinase a Signaling Prevents Liver Ischemia/reperfusion Injury in Mice

Β-Arrestin 2 Inhibits TNFα Induced IKKα/β Activation by Interacting with RIP1

Indispensable Role of Β-Arrestin2 in the Protection of Remifentanil Preconditioning Against Hepatic Ischemic Reperfusion Injury

β-Arrestin prevents cell apoptosis through pro-apoptotic ERK1/2 and p38 MAPKs and anti-apoptotic Akt pathways

Protection Against Hepatic Ischemia/reperfusion Injury Via Downregulation of Toll-Like Receptor 2 Expression by Inhibition of Kupffer Cell Function

KEAP1-NRF2 Complex in Ischemia-Induced Hepatocellular Damage of Mouse Liver Transplants

β-Arrestin 2 regulates toll-like receptor 4-mediated apoptotic signalling through glycogen synthase kinase-3β: β-arrestin 2 regulates TLR4-mediated apoptosis

β-arrestin2: an emerging player and potential therapeutic target in inflammatory immune diseases

β-arrestin2 deficiency ameliorates S-100-induced autoimmune hepatitis in mice by inhibiting infiltration of monocyte-derived macrophage and attenuating hepatocyte apoptosis

β-arrestin 2 regulates Toll-like receptor 4-mediated apoptotic signalling through glycogen synthase kinase-3β.

β-Arrestin-2-ERK1/2 cPLA 2 α axis mediates TLR4 signaling to influence eicosanoid induction in ischemic brain.